medigraphic.com
Asociación Mexicana de Gastroenterología

2005, Number 4

<< Back Next >>

Rev Gastroenterol Mex 2005; 70 (4)

Alternative treatments for patients with chronic C hepatitis who did not respond previous treatments

Diago M

Language: Spanish
References: 22
Page: 458-464
PDF size: 48.31 Kb.


ABSTRACT

Treatment of chronic hepatitis C (HCV) has improved during the last decade with peg Interferon ribavirin (peg IFN-riba) increasing sustained viral response from 6 to 60%. Even though, there is an increasing number of non responding patients that constitutes up to 50% of HCV in referral centers nowdays. This is an heterogenous group for diverse reasons (failure of response to monotherapies, premature drop outs) some of them biologic (genotype I, high viral load, advanced fibrosis, insulin resistance, genetic predisposicition, pharmacologic metabolism) requiring an individualized approach. Unfortunately no new drugs are expected for clinical use before the year 2010. Greater dosages or further prolonged treatments with peg IFN-riba induce remission in up to 60% of these patients. Others require pre-treatment support (antidepresives, eritropoyetin, granulocyte stimulating factor). It is important to establish the goals of treatment: viral eradication or diminish viral load for prevention of complications. Hence it is important to select the group of these patients with greater chances to respond to a second treatment, such as patients with genotypes 2-3, low viral load, failures to monotherapies, recurrences to any treatment, partial responders or those whom had incomplete treatments. Different approach require those that had no response to peg IFN-riba where treatment should be reserved for those with greater risk factors. These need induction regimens with higher dosages during the first 20 weeks and then longer treatment (18-24 months). All of these measures not always eradicate HCV, but do slow fibrosis and its complications: liver failure, portal hypertension and hepatocarcinoma.


REFERENCES

  1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  2. Manns MP, McHutchison JG, Gordon SC, Rutsgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

  3. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa 2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  4. Romero M, Viloria NM, Andrade R, Salmeron J, Diago M, Fernandez C, et al. Insulin resistence impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.

  5. Shiffman M, Di Bisceglie A, Lindsay K, Morishima C, Wright E, Everson G, et al. Peginterferon alfa 2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.

  6. Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J, et al. Sustained Virologic Response in the EPIC3 Trial: Week 12 Virology Predicts SVR in Previous Interferon/Ribavirin Treatment Failures Receiving PEG-Intron®/Rebetol™ Weight Based Dosing. Hepatology 2005; 42 (Suppl. 2): 40.

  7. Herrine S, Brown R, Esposito S. Bernstein D, Te H, Galati, et al. Efficacy and safety of peginterferon alfa 2a combination therapies in patients who relapsed on rebetron therapy. Hepatology 2003; 36: 358A.

  8. Krawitt E, Ashikaga T, Gordon S, Ferrentino N, Ray M, et al. Peginterferon alfa 2b and ribavirin for treatment-refractory chronic hepatitis C. Hepatology 2005; 43: 243-9.

  9. Diago M, Romero-Gomez M, Crespo J, Olveira A, Barcena R, et al. Peginterferon alfa-2a (PEGASYS) and Rivabirin (COPEGUS) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial. Hepatology 2004; 40 (Suppl. 1): 389A.

  10. Lindahl K, Stahle L, Bruchfeld A, Schvarcz. High Dose ribavirin in combination with standar dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-9.

  11. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, et al. Longer treatment duration with peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter Tera ViC-4 Study. Hepatology 2004; 40 (Suppl. 1): 218 A.

  12. Berg T, von Wagner M, Hinrichsen H, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa 2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. Hepatology 2004; 40 (Suppl. 1): 238A.

  13. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. Hepatology 2004; 41: 462-73.

  14. Jensen D, Marcellin P. Rational and design of the REPEAT study: a phase III randomized, clinical trial of peginterferon alfa 2a plus ribavirin in non responders to peginterferon alfa 2b plus ribavirin. Eur J Gastroenterol Hepatol 2005; 17: 899-904.

  15. Goncales F, Bernstein DE, Berg C, Sette H, Rasenack J, Diago M, et al. Peginterferon alfa 2a plus ribavirin in chronic hepatitis C: retreatment of patients who relapsed virologically after 24 weeks of therapy. Hepatology 2002; 36: 361A.

  16. Curry M, Cardenas A, Afdhal N. Effect of maintenance Peg Introm therapy on portal hypertension and its complications: results from the copilot study. Hepatology 2005; 42(Suppl. 2): 40.

  17. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-7.

  18. Rincon D, Bañares R, Ripoll C, Catalina M, Matilla A, Nuñez O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and fibrosis estage 3 or 4. Hepatology 2004; 40 (Suppl. 1): 248A.

  19. Hoofnagle J, Chany M, Kleiner D, Doo E, Heller T, Promrat K, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail tos respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66-74.

  20. Patel K, Dev A, Muir A. McHutchison J. Rivabirin as maintenance therapy for hepatitis C patients: An interim peacekeeper? Hepatology 2003; 38: 21-4.

  21. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens R, Calleja JL, et al. Short term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor in hepatitis C genotype 1 patients. Gastroenterology 2004; 127: 1347-55.

  22. Afdal N, Rodriguez Torres M, Lawitz E, Godofsky E, Chao G, Fielman B, et al. Enhaced antiviral efficacy for valopicitabine (NM283) plus peginterferon in hepatitis C patients with HCV genotype 1 infection: results of a phase I in multicenter trial. J Hepatology 2005; 42(Suppl. 2): 39.




2020     |     www.medigraphic.com